Etofenamate

Identification

Name
Etofenamate
Accession Number
DB08984
Type
Small Molecule
Groups
Approved, Investigational
Description

Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.

Structure
Thumb
Synonyms
  • Etofenamate
External IDs
BAY D 1107 / BAY-D-1107 / TVX-485 / TVX485 / WHR-5020
International/Other Brands
Activon (Meda) / Aspitopic (Bayer) / Bayagel (Bayer) / Bayro (Bayer) / Etobay (Bayer) / Gemadol (Meda) / Glasel (Meda) / Rheumon (Bayer) / Ticatrop (Meda)
Categories
UNII
KZF0XM66JC
CAS number
30544-47-9
Weight
Average: 369.335
Monoisotopic: 369.118792684
Chemical Formula
C18H18F3NO4
InChI Key
XILVEPYQJIOVNB-UHFFFAOYSA-N
InChI
InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2
IUPAC Name
2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate
SMILES
OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(=C1)C(F)(F)F

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Etofenamate is combined with 5-androstenedione.Experimental, Illicit
AbciximabEtofenamate may increase the anticoagulant activities of Abciximab.Approved
AcebutololEtofenamate may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etofenamate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolEtofenamate may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etofenamate.Approved, Vet Approved
AclarubicinEtofenamate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etofenamate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Aldosterone.Experimental, Investigational
AldoxorubicinEtofenamate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.Approved
AliskirenEtofenamate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alminoprofen.Experimental
AlprenololEtofenamate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Etofenamate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Amcinonide.Approved
AmikacinEtofenamate may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideEtofenamate may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinEtofenamate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodEtofenamate may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etofenamate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Etofenamate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Etofenamate is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Anisodamine.Investigational
AnnamycinEtofenamate may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etofenamate.Approved
Antithrombin III humanEtofenamate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanEtofenamate may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Etofenamate is combined with Apocynin.Investigational
ApramycinEtofenamate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Etofenamate.Approved, Investigational
ArbekacinEtofenamate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinEtofenamate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEtofenamate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololEtofenamate may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Atamestane.Investigational
AtenololEtofenamate may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etofenamate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etofenamate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etofenamate.Approved
BalsalazideEtofenamate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminEtofenamate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololEtofenamate may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinEtofenamate may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etofenamate.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etofenamate.Approved
BenorilateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etofenamate.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etofenamate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Betamethasone.Approved, Vet Approved
BetaxololEtofenamate may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Etofenamate.Approved, Investigational
BevantololEtofenamate may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etofenamate.Approved, Investigational
BisoprololEtofenamate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinEtofenamate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololEtofenamate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etofenamate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bucillamine.Investigational
BucindololEtofenamate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bufexamac.Experimental
BufuralolEtofenamate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bumadizone.Experimental
BumetanideEtofenamate may decrease the diuretic activities of Bumetanide.Approved
BupranololEtofenamate may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etofenamate.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etofenamate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etofenamate.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Etofenamate.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Etofenamate is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etofenamate.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Etofenamate.Approved, Vet Approved, Withdrawn
CarteololEtofenamate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolEtofenamate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etofenamate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etofenamate.Approved, Investigational
CeliprololEtofenamate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinEtofenamate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etofenamate.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etofenamate.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etofenamate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etofenamate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etofenamate.Approved
CinoxacinEtofenamate may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidEtofenamate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etofenamate.Vet Approved
CloranololEtofenamate may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Etofenamate is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etofenamate.Experimental
CyclosporineEtofenamate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateEtofenamate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinEtofenamate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEtofenamate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEtofenamate may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinEtofenamate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Etofenamate is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Etofenamate is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Etofenamate.Experimental
DesirudinEtofenamate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etofenamate.Approved, Investigational
DextranEtofenamate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Etofenamate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Etofenamate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Etofenamate may increase the anticoagulant activities of Dextran 75.Approved
DibekacinEtofenamate may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etofenamate.Approved, Vet Approved
DicoumarolEtofenamate may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etofenamate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Etofenamate.Approved
DihydrostreptomycinEtofenamate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Etofenamate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etofenamate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etofenamate.Approved
DoxorubicinEtofenamate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneEtofenamate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Etofenamate is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Etofenamate is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Etofenamate is combined with E-6201.Investigational
Edetic AcidEtofenamate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEtofenamate may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etofenamate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etofenamate.Approved
EnoxacinEtofenamate may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinEtofenamate may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Etofenamate.Experimental
EpanololEtofenamate may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Etofenamate is combined with Epirizole.Approved
EpirubicinEtofenamate may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneEtofenamate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etofenamate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etofenamate.Approved
EquileninThe risk or severity of adverse effects can be increased when Etofenamate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Equilin.Approved
EsmololEtofenamate may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Estrone sulfate.Approved
Etacrynic acidEtofenamate may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etofenamate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ethenzamide.Experimental
Ethyl biscoumacetateEtofenamate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Etofenamate is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Etofenamate.Approved, Investigational, Vet Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Etofenamate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Etofenamate is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Etofenamate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Etofenamate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etofenamate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etofenamate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etofenamate.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Feprazone.Experimental
Ferulic acidEtofenamate may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etofenamate.Approved, Investigational
FleroxacinEtofenamate may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etofenamate.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fludrocortisone.Approved
FluindioneEtofenamate may increase the anticoagulant activities of Fluindione.Investigational
FlumequineEtofenamate may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etofenamate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etofenamate.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etofenamate.Approved, Nutraceutical, Vet Approved
FondaparinuxEtofenamate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEtofenamate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Etofenamate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etofenamate.Approved
FramycetinEtofenamate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideEtofenamate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateEtofenamate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinEtofenamate may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinEtofenamate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Etofenamate.Approved, Withdrawn
GemifloxacinEtofenamate may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinEtofenamate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinEtofenamate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AEtofenamate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Etofenamate may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinEtofenamate may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Etofenamate is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Etofenamate is combined with HE3286.Investigational
HeparinEtofenamate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Higenamine.Investigational
HydralazineEtofenamate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etofenamate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etofenamate.Approved, Investigational
Hygromycin BEtofenamate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etofenamate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Etofenamate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Etofenamate.Approved
IdarubicinEtofenamate may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxEtofenamate may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etofenamate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Etofenamate.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etofenamate.Approved
IndenololEtofenamate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Etofenamate is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etofenamate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etofenamate.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etofenamate.Approved, Investigational
IsepamicinEtofenamate may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etofenamate.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Etofenamate is combined with Istaroxime.Investigational
KanamycinEtofenamate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etofenamate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etofenamate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etofenamate.Approved
LabetalolEtofenamate may decrease the antihypertensive activities of Labetalol.Approved
LandiololEtofenamate may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etofenamate.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Etofenamate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Etofenamate.Approved, Investigational
LepirudinEtofenamate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEtofenamate may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololEtofenamate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinEtofenamate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Etofenamate.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etofenamate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Etofenamate.Approved
LonazolacThe risk or severity of adverse effects can be increased when Etofenamate is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etofenamate.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Etofenamate.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Etofenamate is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etofenamate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Etofenamate.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Etofenamate.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etofenamate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etofenamate.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Etofenamate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etofenamate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etofenamate.Approved
MelagatranEtofenamate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etofenamate.Approved, Vet Approved
MepindololEtofenamate may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineEtofenamate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Etofenamate.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etofenamate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etofenamate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Methylprednisolone.Approved, Vet Approved
MetipranololEtofenamate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate.Approved
MetoprololEtofenamate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideEtofenamate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinEtofenamate may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etofenamate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etofenamate.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etofenamate.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etofenamate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etofenamate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etofenamate.Approved
NadololEtofenamate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinEtofenamate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatEtofenamate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etofenamate.Approved
Nalidixic AcidEtofenamate may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Etofenamate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Etofenamate is combined with NCX 1022.Investigational
NeamineEtofenamate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololEtofenamate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinEtofenamate may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinEtofenamate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etofenamate.Approved
NetilmicinEtofenamate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etofenamate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etofenamate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Nitroaspirin.Investigational
NorfloxacinEtofenamate may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etofenamate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etofenamate.Approved
OlsalazineEtofenamate may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Etofenamate is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Etofenamate.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Orgotein.Vet Approved
OtamixabanEtofenamate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etofenamate.Approved
Oxolinic acidEtofenamate may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololEtofenamate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etofenamate.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Etofenamate.Approved
ParomomycinEtofenamate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Parthenolide.Investigational
PazufloxacinEtofenamate may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinEtofenamate may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololEtofenamate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateEtofenamate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateEtofenamate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etofenamate.Approved
PhenindioneEtofenamate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonEtofenamate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etofenamate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etofenamate.Approved, Investigational
PindololEtofenamate may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidEtofenamate may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinEtofenamate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideEtofenamate may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etofenamate.Approved, Investigational
Piromidic acidEtofenamate may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etofenamate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pirprofen.Experimental
Platelet Activating FactorEtofenamate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinEtofenamate may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinEtofenamate may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etofenamate.Approved
PractololEtofenamate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Etofenamate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Etofenamate can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Propacetamol.Approved, Investigational
PropranololEtofenamate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etofenamate.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etofenamate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Etofenamate.Vet Approved
Protein CEtofenamate may increase the anticoagulant activities of Protein C.Approved
Protein S humanEtofenamate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEtofenamate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinEtofenamate may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Etofenamate.Investigational
PuromycinEtofenamate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etofenamate.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etofenamate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etofenamate.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etofenamate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etofenamate.Approved, Experimental, Investigational
ReviparinEtofenamate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinEtofenamate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Risedronate.Approved, Investigational
RivaroxabanEtofenamate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etofenamate.Investigational, Withdrawn
RosoxacinEtofenamate may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinEtofenamate may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinEtofenamate may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Etofenamate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etofenamate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etofenamate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etofenamate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etofenamate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Etofenamate.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Etofenamate.Approved
SemapimodThe risk or severity of adverse effects can be increased when Etofenamate is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etofenamate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Etofenamate is combined with Serrapeptase.Investigational
SisomicinEtofenamate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinEtofenamate may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Etofenamate.Approved
SotalolEtofenamate may decrease the antihypertensive activities of Sotalol.Approved
SP1049CEtofenamate may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinEtofenamate may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinEtofenamate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Etofenamate.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Etofenamate.Investigational
StreptomycinEtofenamate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinEtofenamate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etofenamate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etofenamate.Approved
SulodexideEtofenamate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Etofenamate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Etofenamate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Suxibuzone.Experimental
TacrolimusEtofenamate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Etofenamate.Approved
TalinololEtofenamate may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Etofenamate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etofenamate.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etofenamate.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etofenamate.Approved, Investigational
TemafloxacinEtofenamate may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Etofenamate.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etofenamate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etofenamate.Approved
TertatololEtofenamate may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etofenamate.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololEtofenamate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tixocortol.Approved, Withdrawn
TobramycinEtofenamate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etofenamate.Approved
TorasemideEtofenamate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etofenamate.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Etofenamate.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etofenamate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etofenamate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Etofenamate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneEtofenamate may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etofenamate.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Etofenamate is combined with Triptolide.Investigational
TrovafloxacinEtofenamate may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinEtofenamate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etofenamate.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etofenamate.Investigational, Withdrawn
ValrubicinEtofenamate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Etofenamate.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Etofenamate.Approved
WarfarinEtofenamate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEtofenamate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etofenamate.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etofenamate.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Etofenamate.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Etofenamate is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etofenamate.Withdrawn
Zoptarelin doxorubicinEtofenamate may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinEtofenamate may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,692,818.

General References
Not Available
External Links
KEGG Drug
D04102
PubChem Compound
35375
PubChem Substance
310264945
ChemSpider
32560
ChEBI
94731
ChEMBL
CHEMBL1451633
Drugs.com
Drugs.com Drug Page
Wikipedia
Etofenamate
ATC Codes
M02AA06 — Etofenamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedDiagnosticDermatitis, Photocontact1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00936 mg/mLALOGPS
logP3.53ALOGPS
logP4.86ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity89.88 m3·mol-1ChemAxon
Polarizability35.57 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Trifluoromethylbenzenes / Aminobenzoic acids and derivatives / Aniline and substituted anilines / Benzoyl derivatives / Vinylogous amides / Amino acids and derivatives / Carboxylic acid esters / Secondary amines / Dialkyl ethers / Monocarboxylic acids and derivatives
show 6 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Trifluoromethylbenzene / Benzoyl / Aniline or substituted anilines / Vinylogous amide / Amino acid or derivatives / Carboxylic acid ester / Carboxylic acid derivative / Secondary amine
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 10, 2014 11:10 / Updated on December 01, 2017 16:11